Literature DB >> 7586375

Combining monophasic action potential recordings with pacing to demonstrate delayed afterdepolarizations and triggered arrhythmias in the intact heart. Value of diastolic slope.

S H de Groot1, M A Vos, A P Gorgels, J D Leunissen, B J van der Steld, H J Wellens.   

Abstract

BACKGROUND: In the intact heart, methodological difficulties hamper the direct visualization of delayed afterdepolarizations (DADs) responsible for triggered arrhythmias. Therefore, we tested the hypothesis that a combination of pacing and the recording of a monophasic action potential (MAP) could facilitate the recognition of ouabain-induced DADs and triggered arrhythmias by demonstrating an increase in the diastolic baseline slope (dV/dT) of the MAP recording at the end of a pacing train. METHODS AND
RESULTS: In anesthetized dogs with chronic atrioventricular block, a right ventricular endocardial MAP was recorded during (1) control (n = 11), (2) 15 to 45 minutes after administration of ouabain (45 +/- 10 micrograms/kg, n = 11), (3) 10 minutes after administration of lidocaine (3 mg/kg, n = 5), and (4) during lidocaine washout (n = 3). Pacing was performed with the MAP catheter. Also, the protocol was performed in 3 dogs with conducted sinus rhythm during control and ouabain circumstances. During control, the slope value was 2 +/- 2 mV/s (mean +/- SD), the incidence of DADs after the stimulation train was 6%, and no ventricular tachycardias (VTs) were induced in dogs with atrioventricular block. During ouabain administration, the slope and DAD incidences increased to, respectively, 26 +/- 14 mV/s and 74% (P < .05 for both). VTs were induced frequently. Lidocaine prevented VT induction by decreasing the slope and the incidence of DADs. This effect disappeared after lidocaine washout. During conducted sinus rhythm, similar results were found.
CONCLUSIONS: By combining pacing and MAP recordings, the diastolic slope observed on MAP recordings in ouabain-intoxicated hearts can be used as a marker for DADs and triggered arrhythmias. This finding may be helpful in identifying triggered activity in the intact heart.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586375     DOI: 10.1161/01.cir.92.9.2697

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model.

Authors:  T Usui; A Sugiyama; Y Ishida; Y Satoh; Y Sasaki; K Hashimoto
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 2.  Animal Models to Study Cardiac Arrhythmias.

Authors:  Daniel J Blackwell; Jeffrey Schmeckpeper; Bjorn C Knollmann
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

3.  Increased intracellular Ca2+ and SR Ca2+ load contribute to arrhythmias after acidosis in rat heart. Role of Ca2+/calmodulin-dependent protein kinase II.

Authors:  M Said; R Becerra; J Palomeque; G Rinaldi; M A Kaetzel; P L Diaz-Sylvester; J A Copello; J R Dedman; C Mundiña-Weilenmann; L Vittone; A Mattiazzi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-22       Impact factor: 4.733

Review 4.  Short-term Variability of Repolarization Is Superior to Other Repolarization Parameters in the Evaluation of Diverse Antiarrhythmic Interventions in the Chronic Atrioventricular Block Dog.

Authors:  Alexandre Bossu; Rosanne Varkevisser; Henriette D M Beekman; Marien J C Houtman; Marcel A G van der Heyden; Marc A Vos
Journal:  J Cardiovasc Pharmacol       Date:  2017-06       Impact factor: 3.105

5.  Altered adrenergic response in myocytes bordering a chronic myocardial infarction underlies in vivo triggered activity and repolarization instability.

Authors:  Eef Dries; Matthew Amoni; Bert Vandenberk; Daniel M Johnson; Guillaume Gilbert; Chandan K Nagaraju; Rosa Doñate Puertas; Mouna Abdesselem; Demetrio J Santiago; H Llewelyn Roderick; Piet Claus; Rik Willems; Karin R Sipido
Journal:  J Physiol       Date:  2020-02-11       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.